Effectiveness of Combination Therapy With Statin and Another Lipid-Modifying Agent Compared With Intensified Statin Monotherapy: A Systematic Review
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Some patients do not tolerate or respond to high-intensity statin monotherapy. Lower-intensity statin combined with nonstatin medication may be an alternative, but the benefits and risks compared with those of higher-intensity statin monotherapy are unclear. PURPOSE: To compare the clinical benefits, adherence, and harms of lower-intensity statin combination therapy with those of higher-intensity statin monotherapy among adults at high risk for atherosclerotic cardiovascular disease (ASCVD). DATA SOURCES: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from inception to July 2013, with an updated MEDLINE search through November 2013. STUDY SELECTION: Randomized, controlled trials published in English. DATA EXTRACTION: Two reviewers extracted information on study design, population characteristics, interventions, and outcomes (deaths, ASCVD events, low-density lipoprotein [LDL] cholesterol level, adherence, and adverse events). Two independent reviewers assessed risk of bias. DATA SYNTHESIS: A total of 36 trials were included. Low-intensity statin plus bile acid sequestrant decreased LDL cholesterol level 0% to 14% more than mid-intensity monotherapy among high-risk hyperlipidemic patients. Mid-intensity statin plus ezetimibe decreased LDL cholesterol level 5% to 15% and 3% to 21% more than high-intensity monotherapy among patients with ASCVD and diabetes mellitus, respectively. Evidence was insufficient to evaluate LDL cholesterol for fibrates, niacin, and ω-3 fatty acids. Evidence was insufficient for long-term clinical outcomes, adherence, and harms for all regimens. LIMITATION: Many trials had short durations and high attrition rates, lacked blinding, and did not assess long-term clinical benefits or harms. CONCLUSION: Clinicians could consider using lower-intensity statin combined with bile acid sequestrant or ezetimibe among high-risk patients intolerant of or unresponsive to statins; however, this strategy should be used with caution given the lack of evidence on long-term clinical benefits and harms. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800742 · Cited by 1,241
Sex/Gender Differences in Cardiovascular Disease Prevention: What a Difference a Decade Makes
Mosca, L., Barrett-Connor, E., & Kass Wenger, N. (2011) · Circulation · doi:10.1161/circulationaha.110.968792 · Cited by 1,045
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group (2010) · The Lancet · doi:10.1016/s0140-6736(10)60310-8 · Cited by 558
Cited by
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 773
Kim, B.-K., Hong, S.-J., Lee, Y.-J., Hong, S. J., Yun, K. H., Hong, B.-K., Heo, J. H., Rha, S.-W., Cho, Y.-H., Lee, S.-J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00916-3 · Cited by 328
Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease
Anstee, Q. M., Mantovani, A., Tilg, H., & Targher, G. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0010-0 · Cited by 310
Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events
Zhan, S., Tang, M., Liu, F., Xia, P., Shu, M., & Wu, X. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012502.pub2 · Cited by 109
The Impact of Statin Intolerance in Lipid Clinic Patients
Williams, K., & Mishra, V. (2015) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2015.65040 · Cited by 1
“Systematic review of 36 clinical trials have shown similar results where low intensity statin in combination with non-statin therapy results in reduction in LDL cholesterol [23] but has insufficient evidence for non-statin monotherapy.”
Result
Metadata
- Authors
- Gudzune, K. A., Monroe, A. K., Sharma, R., Ranasinghe, P. D., Chelladurai, Y., & Robinson, K. A.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2014-04-01
- Volume
- 160
- Issue
- 7
- Pages
- 468-476
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1967861071
- Cited by
- 69
- References
- 15
- FWCI
- 10.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effectiveness of Combination Therapy With Statin and Another Lipid-Modifying Agent Compared With Intensified Statin Monotherapy: A Systematic Review. https://app.cochat.ai/papers/10.7326/m13-2526
- The paper
- Gudzune, K. A., Monroe, A. K., Sharma, R., Ranasinghe, P. D., Chelladurai, Y., & Robinson, K. A. (2014). Effectiveness of Combination Therapy With Statin and Another Lipid-Modifying Agent Compared With Intensified Statin Monotherapy: A Systematic Review. Annals of Internal Medicine. https://doi.org/10.7326/m13-2526
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.